Clinical Research Directory

Inclusion Criteria: * 1\. Subjects with type 2 diabetes mellitus; * 2\. First visit to MMC; * 3\. Age 40-65 years; * 4\. 24.0 \< BMI ≤ 35.0 kg/m2; * 5\. Subjects with screening HbA1c ≥ 7.5% and ≤ 10.0%, and the fasting blood glucose ≥ 8.0 mmol/l and \< 13.3 mmol/l; * 6\. Duration of diabetes less than 10 years; * 7\. Subjects with poorly controlled blood glucose only by 1-2 kinds of non-insulin hypoglycemic drugs for at least 2 months; * 8\. Subjects understand the nature, significance, potential benefits, inconvenience, and risks of the study before it starts, and fully understand the study procedures and voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Subjects with type 1 diabetes, single gene mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes (such as Cushing's syndrome, thyroid dysfunction or acromegaly, etc.); * 2\. Subjects with serious cardiovascular diseases, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy and chronic congestive heart failure (NYHA III-IV); acute myocarditis within 12 months; severe liver and kidney dysfunction (eGFR\<60mL/min/1.73m2); mental disorder, etc. * 3\. Subjects with acute diabetic complications in the past 3 months; * 4\. Subjects who were or are using insulin to control diabetes in the past 3 months; * 5\. History of drug abuse; * 6\. History of sexually transmitted disease (such as syphilis, and HIV infection \[AIDS\], etc.) or in the active phase of infectious disease (such as viral hepatitis, and tuberculosis, etc.); * 7\. Subjects who are pregnant or in lactation; * 8\. Participation in other clinical trials; * 9\. Any condition that in the judgement of the investigator precludes participation. Details please see the study protocol.